Table 2 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors
收藏数据链接：
官方服务：
资源简介：
IRC-assessed endpoints per RECIST v1.1 according to NGS assay type in patients with TMB ≥13 and ≥16 mut/Mb.
创建时间：
2026-03-16
